Syndax Pharmaceuticals (SNDX) Projected to Post Earnings on Tuesday

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) is expected to post its quarterly earnings results before the market opens on Tuesday, February 25th. Analysts expect Syndax Pharmaceuticals to post earnings of ($0.31) per share and revenue of $86.32 million for the quarter.

Syndax Pharmaceuticals Trading Up 2.4 %

NASDAQ SNDX traded up $0.39 during trading hours on Friday, reaching $16.38. The company's stock had a trading volume of 4,008,610 shares, compared to its average volume of 2,311,509. The business has a 50-day simple moving average of $13.97 and a 200 day simple moving average of $16.97. Syndax Pharmaceuticals has a 52 week low of $12.06 and a 52 week high of $25.34. The stock has a market cap of $1.40 billion, a PE ratio of -4.51 and a beta of 0.90.

Insider Buying and Selling at Syndax Pharmaceuticals

In other Syndax Pharmaceuticals news, insider Neil Gallagher sold 4,618 shares of the company's stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $15.50, for a total value of $71,579.00. Following the completion of the sale, the insider now directly owns 85,095 shares in the company, valued at $1,318,972.50. This represents a 5.15 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Michael A. Metzger sold 13,288 shares of Syndax Pharmaceuticals stock in a transaction on Monday, February 10th. The shares were sold at an average price of $15.50, for a total value of $205,964.00. Following the transaction, the chief executive officer now owns 300,121 shares in the company, valued at approximately $4,651,875.50. This trade represents a 4.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 21,683 shares of company stock valued at $336,087. Company insiders own 4.10% of the company's stock.

Analyst Ratings Changes

Several analysts recently issued reports on the company. StockNews.com downgraded Syndax Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday, November 23rd. JPMorgan Chase & Co. raised their target price on Syndax Pharmaceuticals from $33.00 to $38.00 and gave the company an "overweight" rating in a research note on Thursday, November 21st. Scotiabank lowered their price target on shares of Syndax Pharmaceuticals from $18.00 to $16.00 and set a "sector perform" rating for the company in a research report on Wednesday, January 8th. UBS Group assumed coverage on shares of Syndax Pharmaceuticals in a report on Thursday, October 24th. They issued a "buy" rating and a $37.00 price objective on the stock. Finally, The Goldman Sachs Group boosted their target price on shares of Syndax Pharmaceuticals from $30.00 to $33.00 and gave the company a "buy" rating in a research note on Thursday, November 7th. One analyst has rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $36.20.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).